News

Under the trial, Mesoblast carried out a post-hoc analysis in 30 patients who were randomized to receive either placebo or a single administration of 150 million MPCs (MPC-150-IM).

Novavax expects to start the trial during the first quarter of next year. The grant will also support the company’s regulatory licensing initiatives for WHO prequalification. After licensing,

The complaint filed by the U.S. Department of Justice sought the permanent injunction against the company and its owners for manufacturing dietary supplements under conditions that do not

Under the multinational, double-blind placebo-controlled Phase III HERCULES study, the company will enroll 92 patients at clinical sites across 17 countries. The primary endpoint of the study is

GvHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body. Under the new

About $29.5m will support studies on caring for people affected with hepatitis C virus (HCV). Awards totaling around $7.4m will fund research on rare conditions in response to

The deal will allow Lilly and its German partner, Boehringer Ingelheim, to launch the product in the US in late 2016. Basaglar secured approval from the US Food

In August, NYBC announced a partnership with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for the repair and

The company worked with the US and European regulators to carry out its pivotal study under one global protocol for evaluating safety and efficacy of VTS-270. Vtesse will